Today, net, which in product Puma impacted as royalties reported million and was call net million reported QX million all of million QX by XXXX. of you $XX.X includes sales the reported entirely third from $X.X joining $XX.X consists quarter increase of of both the distributors. XXXX, increase total and the from specialty Mariann, XXXX XXXX quarter sublicensees. revenue the you, pharmacies for an approximately in of Product which quarter for the at $XX.X as our our for was revenue $XX.X was XXXX Thank Product third revenue and revenue today. well our of inventory in third specialty NERLYNX thank Total revenue million.
Royalty revenue Royalty was in $XX.X China third our million quarter QX included XXXX in and million the XXXX. August quarter we Fabre, partner, Pierre in noted to offshore of sales as compared in of million our revenue by latest $X.X in results. the forecast expected the XXXX XXXX to $X.X QX QX
X% X,XXX NERLYNX estimate sold by third of XXXX. 'XX, up comments prescriptions and slides. to QX Jeff and compared further prescriptions to XX bottles. QX the reported X,XXX from sold XXXX, essentially provide compared XXXX QX that In his XXXX. in We in were an were quarter about increase In will XXXX, details bottles XXX new of total flat we increased QX of inventory bottles in QX the
will of XXXX. highlights third on Jeff Maximo review will Nougues Ludwig then will then with follow the NERLYNX I key of components of financial statements the and activities. a our quarter now clinical commercial provide quarter, for color address our of the additional
in was the where in lung patients goal role. and kinase with the correlate believes X the the to biomarker The subgroups the efficacy accelerated with has efficacy that comparable small paclitaxel cancer in an II trial study discussed, it was data strategy a FDA study plus monotherapy paclitaxel of biomarkers in from that previously the alisertib, would drug, investigational of plus company Puma to ALISCA-LungX efficacy ongoing to XXXX. a discuss placebo biomarker alisertib versus of alisertib the Phase our engage studies, seen If randomized to pathway the are potential is Journal cell aurora subgroups As efficacy and of confirm the plays the these in published would further. the from Thoracic biomarker Oncology previously in this represent approval
with XX with XXXX. as trial neutropenia, febrile a In As this X% cell investors results small the discontinued drug-related remember, X/X patients equals patients showed experienced cell the Lancet as grade due alisertib trial the and was Oncology published trial, alisertib a XX% was neutropenia will in to this lung cancer. patients cancer, monotherapy to and administered lung small X/X monotherapy tested of of previously in from patients were XX% events. the experienced and The that grade treatment safety adverse of results in
evaluable of chemotherapy-resistant relapsed patients, showed PFS patients that months. X.X was chemotherapy-sensitive XX a X.X population for objective or rate efficacy XX the The PFS response and XX% the of rate objective the response And with the efficacy XX% an the for XX results patients, was from months. was
patients X XX comparator milligrams for to XX monotherapy the on of placebo whereas versus alisertib plus will weeks X intravenously administered dose XX XX investors mg days received BID also was patients trial, with to dosed Journal published was cell trial XX, in paclitaxel plus XXXX. small X per Thoracic paclitaxel lung plus days a milligrams paclitaxel II X tested paclitaxel As in which than of Alisertib Oncology alisertib randomized XX XX arm plus incorporated outcome. remember, c-Myc with a and to X, results trial a well The IV on previously of analysis discontinued an of the at second-line placebo the also because and XX% X being neutropenia febrile with was X, clinical an with grade of meter in because the at analysis Phase event. and in XX of patients cancer, drug-related from alisertib in different adverse on cycles.
The a also of higher had or the event, in of as that extensive grade squared analysis arm treatment days the adverse alterations biomarker genetic experienced showed in dose safety the XX% a trial or study of and ctDNA X with experiencing an the retrospective reduction X, of prespecified expression higher neutropenia. X XX% as XX-day XX% patients combination
was survival of endpoint PFS. primary trial The progression-free that or
PFS of the for using with X.XX for the For hazard with the for was p-value PFS a relapse corrected of was When of hazard ratio definition the the type, population, X.XX X.XXX. ITT ratio X.XXX. a p-value stratification
with refractory disease, ratio X.XXX. of hazard resistant or the a with was X.XX patients For chemotherapy the p-value
and the X.XXX be patients With respect the that arm biomarkers placebo for who p-value X.XXX. to with X.X months, trial PFS patients placebo found X.XXX the the arm for cell ratio that the a for and in the and the arm median PFS in of X.XX arm was to trial, that months ratio hazard plus for paclitaxel the ratio cycle a for X.XXXXX. CDKX, and a for median subgroup for X.XX the RBLX, genes, Also while months plus of the RBX, expression, alisertib was c-Myc of placebo were and of of for arm alisertib months paclitaxel alterations PFS IHC-positive plus paclitaxel trial X.X hazard X.XX X.XX was months. hazard with with was were months, was of The paclitaxel for including in a X.XX the the plus PFS alisertib survival arm overall studied with p-value a for RBLX in patients the
giving focuses instituted was of When Puma licensed the XX of ALISCA-LungX patients ALISCA-LungX trial. our prophylactic by alisertib, is and this the to in the event in of screening X/X one trial being and G-CSF with the grade try with we enrolled Currently, are adverse in more and the neutropenia prescreening. reduce to several stated that specifically, the administration drug alisertib, there profile
required the For X.X% and who alisertib patient and a has to alisertib company is patient, in X.X% X the this grade increase XX X/X safety, potential due has neutropenia. were preliminary patient No first to be neutropenia monotherapy X the has X seen, to febrile and trial. and discontinued on being X.X% continues seen improved that in of the the dose with considering the neutropenia the with is events available hold. adverse dose or Based been or trial tolerability there for patients patient assuming
combination which assessment. assuming resistant Of to XX refractory increase defined less as tolerability dose is able may days be of treatment with and this that less the XX have neutropenia combined with XX paclitaxel continues given more had the better be of primary days company after X alisertib patients paclitaxel. XX the relapse with X had Also, XXX or disease, a and Of relapsed improved to days alisertib tumor these, seen dosed chemotherapy had may is to that is than alisertib as believes chemotherapy-sensitive a with the be able that after and than post-baseline treatment. paclitaxel, of than but primary result disease, alisertib, efficacy defined in company when it the
patient and been has resistant In response with been the X.X or been PFS X with X months. median disease, patients partial has the and the X.X In with chemotherapy-sensitive months. PFS or stable or patients, or has median patient patients disease, chemotherapy XX% refractory stable X XX% XX% shown have there and a disease the
analysis correlate responses extensive the biomarkers aurora with clinical or with partial As are it gains. pathway previously MYC see biomarkers the with conducting with resistant kinase activation, correlates we the including The an pathway to if mutations that involved and of that kinase be to activation, X RBX mentioned, refractory are have known patients did aurora outcome.
early on We patients all data, tissue caution that this the have do very we enrolled. and not is
with between patients to definitive small and So the the conclusions number biomarkers be is able draw on associations of data too alisertib biomarker to activity.
trial trial continue preliminary be of Oncology to company that and Journal presented in anticipates chemotherapy a the what resistant similar Thoracic believes disease, Lancet Oncology. trial refractory was published in activity ALISCA-X is of in patients which is from at medical The preliminary conferences enrollment the the company better in providing to The randomized data XXXX. trials published or that potentially in in with ALISCA-X was the the The will the additional seen and plans data indication
drug cell this to also steps in progresses. the will company to next with The it The its keep committee order plans on patients. the company of the investors for updated for lung treatment meet small the trial as cancer in determine steering
the it will patients as trial Investors test plans for have positive will Currently, and the ALISCA-BreastX combination in to the in breast cancer. fourth remember trial in on Phase in II chemotherapy-naive the of receptor treatment there endocrine with progresses. initiation quarter company keep a trial, hormone sites HERX-negative with trial, the metastatic that The that alisertib alisertib also are investors been updated anticipate X this company the XXXX. activated we of of
it on As investor mentioned evaluate response in-license prior continues call the and over infrastructure. will the a on diversify our commercial that will earnings drugs to will regulatory to questions, investors Officer, of in Puma Chief Jeff The leverage and existing allow updated itself Puma's and turn company to to R&D, during Commercial calls review quarter. this progresses.
I for company the commercial potentially keep several Puma's now performance to as Ludwig,
